Brief: TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension
03/11/2025 11:40
Nov 3 (Reuters) - TScan Therapeutics Inc TCRX.O: TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 AND ANNOUNCES STRATEGIC PRIORITIZATION TO ADVANCE TSC-101 AND EXTEND CASH RUNWAY INTO H2 2027 TSCAN THERAPEUTICS INC - ANNOUNCES 30% WORKFORCE REDUCTION AND CASH RUNWAY EXTENSION TSCAN THERAPEUTICS INC: STRATEGIC PRIORITIZATION EXTENDS CASH RUNWAY INTO H2 2027 TSCAN THERAPEUTICS INC - EXPECTS $45 MILLION ANNUAL SAVINGS FROM STRATEGIC PRIORITIZATION TSCAN THERAPEUTICS INC - TO BEGIN TSC-101 PIVOTAL TRIAL IN Q2 2026 TSCAN: PAUSED FURTHER ENROLLMENT OF PATIENTS WITH MULTIPLEX TCR-T THERAPY TO PRIORITIZE HEME DEVELOPMENT; REITERATES PLANNED DATA READOUT IN Q1 2026 Source text: ID:nGNX40nw9W Further company coverage: TCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing